

STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 121208

TO: David Lukton
Location: REM-3B75&3C70
Art Unit: 1653
Wednesday, May 05, 2004

Case Serial Number: 09/961376

From: Mary Jane Ruhl
Location: Biotech-Chem Library
Remsen 1-B55
Phone: 571-272-2524

maryjane.ruhl@uspto.gov

Search Notes

Examiner Lukton,

Here are the results for your recent search request.

Please feel free to contact me if you have any questions about these results.

Thank you for using STIC services. We appreciate the opportunity to serve you.

Sincerely,

Mary Jane Ruhl
Technical Information Specialist
STIC
CM-1, Rm. 6-A-06
605-1155



STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact *the searcher or contact:*

Mary Hale, Information Branch Supervisor
571-272-2507 Remsen E01 D86

Voluntary Results Feedback Form

- *I am an examiner in Workgroup:* Example: 1610
- *Relevant prior art found*, search results used as follows:
- 102 rejection
 - 103 rejection
 - Cited as being of interest.
 - Helped examiner better understand the invention.
 - Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- Foreign Patent(s)
- Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ *Relevant prior art not found:*

- Results verified the lack of relevant prior art (helped determine patentability).
- Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC/Biotech-Chem Library Remsen Bldg.

=> d his ful

(FILE 'HOME' ENTERED AT 15:00:57 ON 05 MAY 2004)

FILE 'HCAPLUS' ENTERED AT 15:01:12 ON 05 MAY 2004

E TERNANSKY ROBERT J/AU

L1 51 SEA ABB=ON ("TERNANSKY ROBERT"/AU OR "TERNANSKY ROBERT J"/AU
OR "TERNANSKY ROBERT JOHN"/AU OR "TERNANSKY ROBERTJ"/AU)
E GLADSTONE PATRICIA L/AU

L2 16 SEA ABB=ON ("GLADSTONE PATRICIA L"/AU OR "GLADSTONE PATRICIA
LOUISE"/AU OR "GLADSTONE PATRICIAL"/AU)
E TOMASELLI KEVIN J/AU

L3 75 SEA ABB=ON ("TOMASELLI KEVIN"/AU OR "TOMASELLI KEVIN J"/AU OR
"TOMASELLI KEVIN JAMES"/AU)
E CHAO BIN/AU

L4 16 SEA ABB=ON "CHAO BIN"/AU

L5 15 SEA ABB=ON ("LINTON STEVEN D"/AU OR "LINTON STEVEN DOUGLAS"/AU
)

L6 1 SEA ABB=ON L1 AND L2 AND L3 AND L4 AND L5
SELECT RN L6 1-1

Improve search

FILE 'HCAPLUS' ENTERED AT 15:02:47 ON 05 MAY 2004

FILE 'REGISTRY' ENTERED AT 15:02:50 ON 05 MAY 2004

L7 38 SEA ABB=ON (122191-40-6/B1 OR 146398-02-9/B1 OR 169592-56-7/B1
OR 179241-78-2/B1 OR 182372-15-2/B1 OR 254751-08-1/B1 OR
3144-09-0/B1 OR 350606-03-0/B1 OR 350606-06-3/B1 OR 350606-07-4
/B1 OR 350606-08-5/B1 OR 350606-09-6/B1 OR 350606-10-9/B1 OR
350606-12-1/B1 OR 350606-14-3/B1 OR 350606-16-5/B1 OR 350606-18
-7/B1 OR 350606-19-8/B1 OR 350606-20-1/B1 OR 35661-39-3/B1 OR
42289-34-9/B1 OR 461009-53-0/B1 OR 461009-54-1/B1 OR 461009-55-
2/B1 OR 461009-56-3/B1 OR 461009-57-4/B1 OR 461009-58-5/B1 OR
461009-59-6/B1 OR 461009-60-9/B1 OR 461009-61-0/B1 OR 461009-62
-1/B1 OR 461009-63-2/B1 OR 461009-64-3/B1 OR 461009-65-4/B1 OR
461009-66-5/B1 OR 5545-52-8/B1 OR 6306-52-1/B1 OR 86060-84-6/B1
)

FILE 'HCAPLUS' ENTERED AT 15:02:59 ON 05 MAY 2004

L8 1 SEA ABB=ON L6 AND L7
D IBIB ABS HITSTR L8 1-1

FILE 'REGISTRY' ENTERED AT 15:08:08 ON 05 MAY 2004

L9 STR

L10 0 SEA SSS SAM L9

L11 7 SEA SSS FUL L9 *7 records from Reg*

FILE 'HCAPLUS' ENTERED AT 15:18:01 ON 05 MAY 2004

L12 2 SEA ABB=ON L11 *2 cits from CAPlus - see d/qne stat
(inventories) L12*

FILE 'REGISTRY' ENTERED AT 15:18:46 ON 05 MAY 2004

L13 STR L9

L14 0 SEA SSS SAM L13

L15 0 SEA SSS FUL L13


L16 STR L13

0 hits for "ring or chain" - see d/qne stat L15

FILE 'CAOLD' ENTERED AT 15:28:16 ON 05 MAY 2004

L17 0 SEA ABB=ON L11

=> d que stat l12
 L9 STR



REP G1=(1-2) CH2

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 19


STEREO ATTRIBUTES: NONE

L11 7 SEA FILE=REGISTRY SSS FUL L9

L12 2 SEA FILE=HCAPLUS ABB=ON L11

=> d que stat 115
 'L15\' IS NOT VALID HERE
 For an explanation, enter "HELP DISPLAY QUERY".

=> d que stat 115
 L13 STR



NODE ATTRIBUTES:

NSPEC IS RC AT 26

NSPEC IS RC AT 27

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE

L15 0 SEA FILE=REGISTRY SSS FUL L13

100.0% PROCESSED 18 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

SEARCH REQUEST FORM (STIC)

Requestor's Name: David Lukton Examiner number: 71263 Date: 5/5/04

Mail Box: 3-C-70 Examiner Rm: 3-B-75 Results format: paper

* * * * *

Title: Inhibitors of the ICE/CED family of cysteine proteases.

Applicants: TERNANSKY, ROBERT J.; GLADSTONE, PATRICIA L.; TOMASELLI, KEVIN J.; CHAO, BIN; LINTON, STEVEN D.

Earliest Priority Date: 1/13/00

* * * *

Applicants are claiming the compounds on the attached sheet

R¹ = anything

R^2 = anything

\mathbb{R}^3 = anything

\mathbb{R}^4 = anything;

or R^3 and R^4 , with the atoms to which they are attached, form a ring.


X = anything

R^5 = anything

n = an integer of 1 or 2

p = an integer of 1 or 2

09-908969





=> d ibib abs hitstr 112 1-2

L12 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:736881 HCAPLUS
 DOCUMENT NUMBER: 137:247931
 TITLE: Preparation of novel oxamyl dipeptide inhibitors of
 the ICE/ced-3 family of cysteine proteases
 INVENTOR(S): Ternansky, Robert J.; Gladstone, Patricia L.;
 Tomaselli, Kevin J.; Chao, Bin; Linton, Steven D.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 31 pp., Cont.-in-part of U.S.
 Ser. No. 482,813.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002137686	A1	20020926	US 2001-908969	20010718
US 6515173	B1	20030204	US 2000-482813	20000113
WO 2003008374	A1	20030130	WO 2002-US23025	20020718
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1406866	A1	20040414	EP 2002-753400	20020718
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.: US 2000-482813 A2 20000113 US 2001-908969 A 20010718 WO 2002-US23025 W 20020718				

OTHER SOURCE(S): MARPAT 137:247931
 GI



AB Title compds. I [p, q = 1 or 2; R, R1 = alkyl, cycloalkyl, Ph, etc. or R1R1'N = (un)substituted heterocyclyl; A = (un)natural amino acid; B = H, alkyl, cycloalkyl, etc.], novel oxamyl dipeptide ICE/ced-3 family inhibitors, useful in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure, were prepared E.g., a multi-step synthesis of II which showed Ki of 0.004, 0.856, 0.681, and 0.011 μ M in the mICE, CPP32, MCH2, and MCH5 assays, resp., was given.

IT 350606-03-0P 461009-61-0P 461009-62-1P

461009-63-2P 461009-64-3P 461009-65-4P

461009-66-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel oxamyl dipeptide inhibitors of the ICE/ced-3 family of cysteine proteases)

RN 350606-03-0 HCPLUS

CN L-Alaninamide, N-[2-(1,1-dimethylethyl)phenyl]-2-oxoglycyl-N-[(1S)-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461009-61-0 HCPLUS

CN L-Valinamide, N-[2-(1,1-dimethylethyl)phenyl]-2-oxoglycyl-N-[(1S)-1-formyl-3-[(methylsulfonyl)amino]-3-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461009-62-1 HCPLUS

CN L-Valinamide, 2-oxo-N-[2-(phenylmethyl)phenyl]glycyl-N-[(1S)-1-formyl-3-[(methylsulfonyl)amino]-3-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461009-63-2 HCPLUS

CN L-Valinamide, N-(2-bromophenyl)-2-oxoglycyl-N-[(1S)-1-formyl-3-[(methylsulfonyl)amino]-3-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461009-64-3 HCPLUS

CN L-Alaninamide, N-(2-bromophenyl)-2-oxoglycyl-N-[(1S)-1-formyl-3-[(methylsulfonyl)amino]-3-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461009-65-4 HCPLUS

CN L-Alaninamide, N-[2-(1,1-dimethylethyl)phenyl]-2-oxoglycyl-N-[(1S)-1-formyl-3-[(methylsulfonyl)amino]-3-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461009-66-5 HCPLUS

CN L-Alaninamide, 2-oxo-N-[2-(phenylmethyl)phenyl]glycyl-N-[(1S)-1-formyl-3-[(methylsulfonyl)amino]-3-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 2 OF 2 HCPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:526054 HCPLUS

DOCUMENT NUMBER: 135:107583

TITLE: Preparation of novel oxamyl dipeptide inhibitors of the ICE/ced-3 family of cysteine proteases

INVENTOR(S): Ternansky, Robert J.; Gladstone, Patricia L.; Tomaselli, Kevin J.

PATENT ASSIGNEE(S): Idun Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 57 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051462	A1	20010719	WO 2001-US1006	20010110
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6515173	B1	20030204	US 2000-482813	20000113
EP 1261583	A1	20021204	EP 2001-942358	20010110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003519680	T2	20030624	JP 2001-551844	20010110
PRIORITY APPLN. INFO.:			US 2000-482813	A 20000113
			WO 2001-US1006	W 20010110
OTHER SOURCE(S): GI		MARPAT 135:107583		



AB The title compds. [I; p = 1-2; q = 1-2; R, R1 = alkyl, cycloalkyl, Ph, etc.; A = (un)natural amino acid; B = H, alkyl, cycloalkyl, etc.], novel oxamyl dipeptide ICE/ced-3 family inhibitors, useful in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure, were prepared E.g., a multi-step synthesis of II which showed Ki of 0.004, 0.856, 0.681, and of 0.011 μ M in the mICE, CPP32, Mch2, and Mch5 assays, resp., was given.


IT 350606-03-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel oxamyl dipeptide inhibitors of the ICE/ced-3 family of cysteine proteases)

RN 350606-03-0 HCAPLUS

CN L-Alaninamide, N-[2-(1,1-dimethylethyl)phenyl]-2-oxoglycyl-N-[(1S)-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Lukton 09/908,969

05/05/2004

REFERENCE COUNT:

3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Inventor Search



Lukton 09/908,969

05/05/2004

=> d ibib abs hitstr 18 1-1

L8 ANSWER 1 OF 1 HCPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:736881 HCPLUS
DOCUMENT NUMBER: 137:247931
TITLE: Preparation of novel oxamyl dipeptide inhibitors of the ICE/ced-3 family of cysteine proteases
INVENTOR(S): Ternansky, Robert J.; Gladstone, Patricia L.; Tomaselli, Kevin J.; Chao, Bin; Linton, Steven D.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 31 pp., Cont.-in-part of U.S. Ser. No. 482,813.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002137686	A1	20020926	US 2001-908969	20010718
US 6515173	B1	20030204	US 2000-482813	20000113
WO 2003008374	A1	20030130	WO 2002-US23025	20020718
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1406866	A1	20040414	EP 2002-753400	20020718
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.:			US 2000-482813	A2 20000113
			US 2001-908969	A 20010718
			WO 2002-US23025	W 20020718
OTHER SOURCE(S):		MARPAT 137:247931		
GI				



AB Title compds. I [p, q = 1 or 2; R, R1 = alkyl, cycloalkyl, Ph, etc. or R1R1'N = (un)substituted heterocyclyl; A = (un)natural amino acid; B = H, alkyl, cycloalkyl, etc.], novel oxamyl dipeptide ICE/ced-3 family inhibitors, useful in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure, were prepared E.g., a multi-step synthesis of II which showed Ki of 0.004, 0.856, 0.681, and 0.011 μ M in the mICE, CPP32, MCH2, and MCH5 assays, resp., was given.

IT 122191-40-6 169592-56-7, Apopain 179241-78-2

182372-15-2

RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)

(preparation of novel oxamyl dipeptide inhibitors of the ICE/ced-3 family of cysteine proteases)

RN 122191-40-6 HCAPLUS

CN Proteinase, interleukin 1 β precursor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 169592-56-7 HCAPLUS

CN Apopain (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 179241-78-2 HCAPLUS

CN Proteinase, FLICE (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 182372-15-2 HCAPLUS

CN Proteinase, Mch2 α (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 350606-03-0P 461009-61-0P 461009-62-1P

461009-63-2P 461009-64-3P 461009-65-4P

461009-66-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel oxamyl dipeptide inhibitors of the ICE/ced-3 family of cysteine proteases)

RN 350606-03-0 HCAPLUS

CN L-Alaninamide, N-[2-(1,1-dimethylethyl)phenyl]-2-oxoglycyl-N-[(1S)-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461009-61-0 HCAPLUS

CN L-Valinamide, N-[2-(1,1-dimethylethyl)phenyl]-2-oxoglycyl-N-[(1S)-1-formyl-3-[(methylsulfonyl)amino]-3-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461009-62-1 HCAPLUS

CN L-Valinamide, 2-oxo-N-[2-(phenylmethyl)phenyl]glycyl-N-[(1S)-1-formyl-3-[(methylsulfonyl)amino]-3-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461009-63-2 HCPLUS

CN L-Valinamide, N-(2-bromophenyl)-2-oxoglycyl-N-[(1S)-1-formyl-3-[(methylsulfonyl)amino]-3-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461009-64-3 HCPLUS

CN L-Alaninamide, N-(2-bromophenyl)-2-oxoglycyl-N-[(1S)-1-formyl-3-[(methylsulfonyl)amino]-3-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461009-65-4 HCPLUS

CN L-Alaninamide, N-[2-(1,1-dimethylethyl)phenyl]-2-oxoglycyl-N-[(1S)-1-formyl-3-[(methylsulfonyl)amino]-3-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 461009-66-5 HCPLUS

CN L-Alaninamide, 2-oxo-N-[2-(phenylmethyl)phenyl]glycyl-N-[(1S)-1-formyl-3-[(methylsulfonyl)amino]-3-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 3144-09-0, Methanesulfonamide 5545-52-8
6306-52-1, L-Valine methyl ester hydrochloride 35661-39-3
42289-34-9 86060-84-6 254751-08-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of novel oxamyl dipeptide inhibitors of the ICE/ced-3 family of
cysteine proteases)
RN 3144-09-0 HCAPLUS
CN Methanesulfonamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 5545-52-8 HCAPLUS
CN L-Aspartic acid, N-[(phenylmethoxy)carbonyl]-, 4-(1,1-dimethylethyl) ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 6306-52-1 HCAPLUS
CN L-Valine, methyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 35661-39-3 HCAPLUS


CN L-Alanine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 42289-34-9 HCAPLUS

CN Phenol, 2,3,5,6-tetrafluoro-, potassium salt (9CI) (CA INDEX NAME)




● K


RN 86060-84-6 HCAPLUS

CN L-Aspartic acid, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-, 4-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 254751-08-1 HCPLUS
 CN Acetic acid, [(2-(1,1-dimethylethyl)phenyl]amino]oxo- (9CI) (CA INDEX NAME)




IT 146398-02-9P 350606-06-3P 350606-07-4P
 350606-08-5P 350606-09-6P 350606-10-9P
 350606-12-1P 350606-14-3P 350606-16-5P
 350606-18-7P 350606-19-8P 350606-20-1P
 461009-53-0P 461009-54-1P 461009-55-2P
 461009-56-3P 461009-57-4P 461009-58-5P
 461009-59-6P 461009-60-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of novel oxamyl dipeptide inhibitors of the ICE/ced-3 family of cysteine proteases)
 RN 146398-02-9 HCPLUS
 CN Butanoic acid, 4-hydroxy-3-[(phenylmethoxy)carbonyl]amino-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 350606-06-3 HCPLUS
 CN Pentanoic acid, 5-bromo-3-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-oxo-, phenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 350606-07-4 HCPLUS

CN Pentanoic acid, 3-[(9H-fluoren-9-ylmethoxy)carbonylamino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, phenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 350606-08-5 HCPLUS

CN D-glycero-Pentonic acid, 2,3-dideoxy-3-[(9H-fluoren-9-ylmethoxy)carbonylamino]-5-O-(2,3,5,6-tetrafluorophenyl)-, phenylmethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 350606-09-6 HCPLUS

CN D-glycero-Pentonic acid, 2,3-dideoxy-3-[(9H-fluoren-9-

ylmethoxy)carbonyl]amino]-5-O-(2,3,5,6-tetrafluorophenyl)-4-O-(tetrahydro-2H-pyran-2-yl)-, phenylmethyl ester, (4ξ)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 350606-10-9 HCAPLUS

CN D-glycero-Pentonic acid, 3-amino-2,3-dideoxy-5-O-(2,3,5,6-tetrafluorophenyl)-4-O-(tetrahydro-2H-pyran-2-yl)-, phenylmethyl ester, (4ξ)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 350606-12-1 HCAPLUS


CN D-glycero-Pentonic acid, 2,3-dideoxy-3-[(2S)-2-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-1-oxopropyl]amino]-5-O-(2,3,5,6-tetrafluorophenyl)-4-O-(tetrahydro-2H-pyran-2-yl)-, phenylmethyl ester, (4ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 350606-14-3 HCPLUS
 CN D-glycero-Pentonic acid, 3-[(2S)-2-amino-1-oxopropyl]amino]-2,3-dideoxy-5-O-(2,3,5,6-tetrafluorophenyl)-4-O-(tetrahydro-2H-pyran-2-yl)-, phenylmethyl ester, (4ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 350606-16-5 HCPLUS
 CN D-glycero-Pentonic acid, 2,3-dideoxy-3-[(2S)-2-[[[2-(1,1-dimethylethyl)phenyl]amino]oxoacetyl]amino]-1-oxopropyl]amino]-5-O-(2,3,5,6-tetrafluorophenyl)-4-O-(tetrahydro-2H-pyran-2-yl)-, phenylmethyl ester, (4ξ)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 350606-18-7 HCPLUS

CN D-glycero-Pentonamic acid, 2,3-dideoxy-3-[(2S)-2-[[[2-(1,1-dimethylethyl)phenyl]amino]oxoacetyl]amino]-1-oxopropyl]amino]-5-O-(2,3,5,6-tetrafluorophenyl)-4-O-(tetrahydro-2H-pyran-2-yl)-, (4ξ)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 350606-19-8 HCPLUS

CN D-glycero-Pentonamide, 2,3-dideoxy-3-[(2S)-2-[[[2-(1,1-dimethylethyl)phenyl]amino]oxoacetyl]amino]-1-oxopropyl]amino]-N-(phenylsulfonyl)-5-O-(2,3,5,6-tetrafluorophenyl)-4-O-(tetrahydro-2H-pyran-2-yl)-, (4ξ)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 350606-20-1 HCAPLUS

CN D-glycero-Pentonamide, 2,3-dideoxy-3-[(2S)-2-[[[2-(1,1-dimethylethyl)phenyl]amino]oxoacetyl]amino]-1-oxopropylamino]-N-(phenylsulfonyl)-5-O-(2,3,5,6-tetrafluorophenyl)-, (4ξ)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461009-53-0 HCAPLUS

CN Butanoic acid, 4-[(1,1-dimethylethyl)diphenylsilyl]oxy]-3-[(phenylmethoxy)carbonylamino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461009-54-1 HCAPLUS

CN Butanoic acid, 4-[(1,1-dimethylethyl)diphenylsilyl]oxy]-3-[(phenylmethoxy)carbonylamino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461009-55-2 HCAPLUS

CN Carbamic acid, [(1S)-1-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-3-[(methylsulfonyl)amino]-3-oxopropyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461009-56-3 HCAPLUS

CN Butanamide, 3-amino-4-[(1,1-dimethylethyl)diphenylsilyl]oxy-N-(methylsulfonyl)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461009-57-4 HCAPLUS

CN L-Valine, N-[2-(1,1-dimethylethyl)phenyl]-2-oxoglycyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461009-58-5 HCAPLUS

CN L-Valine, N-[2-(1,1-dimethylethyl)phenyl]-2-oxoglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 461009-59-6 HCAPLUS

CN Ethanediamide, N-[(1S)-1-[[[[(1S)-1-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-3-[(methylsulfonyl)amino]-3-oxopropyl]amino]carbonyl]-2-methylpropyl]-N'-[2-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 461009-60-9 HCAPLUS

CN L-Valinamide, N-[2-(1,1-dimethylethyl)phenyl]-2-oxoglycyl-N-[(1S)-1-(hydroxymethyl)-3-[(methylsulfonyl)amino]-3-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Lukton 09/908, 969

05/05/2004



=>